QGEN:NYSE (Netherlands) Also trade in: Austria Germany Switzerland UK

Qiagen NV

$ 38.3 -0.23 (-0.6%)
Volume: 1,853,908 Avg Vol (1m): 1,211,239
Market Cap $: 8.64 Bil Enterprise Value $: 9.42 Bil
P/E (TTM): 46.71 P/B: 3.29
Earnings Power Value 4.72
Net Current Asset Value -4.24
Tangible Book 0.23
Projected FCF 18.33
Median P/S Value 28.18
Graham Number 2.05
Peter Lynch Value 5.39
DCF (FCF Based) 9.57
DCF (Earnings Based) 8.78
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt 0.64
Equity-to-Asset 0.46
Debt-to-Equity 0.83
Debt-to-EBITDA 4.35
Interest Coverage 3.96
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.68
DISTRESS
GREY
SAFE
Beneish M-Score -2.61
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 6.69%
WACC 5.1%

Profitability & Growth : 7/10

Current vs industry vs history
Operating Margin % 17.75
Net Margin % 12.68
ROE % 7.43
ROA % 3.59
ROC (Joel Greenblatt) % 39.65
3-Year Total Revenue Growth Rate 5.40
3-Year Total EBITDA Growth Rate 11.00
3-Year EPS w/o NRI Growth Rate 14.20

» QGEN's 30-Y Financials

Financials (Next Earnings Date: 2019-05-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:QGEN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 541720    SIC : 8733
Compare NYSE:BIO NYSE:PKI NAS:DXCM NAS:ICLR NAS:EXAS XTER:AFX XPAR:ERF XPAR:BIM NAS:PRAH SZSE:300676 MIL:DIA NYSE:CRL XTER:SRT3 NAS:BRKR SHSE:603658 NAS:SYNH NAS:NEOG NAS:FMI BSP:DASA3 BSP:FLRY3
Traded in other countries QIA.Germany 0RLT.UK
Address Hulsterweg 82, Venlo, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company operates in four segments: molecular diagnostics (50% of sales), academia (21%), pharmaceutical (20%), and applied testing (9%). Qiagen generates about 87% of its revenue from consumable sales and 13% from instrumentation. The Americas account for the largest portion of the firm's revenue (46%), followed by EMEA (34%) and Asia-Pacific (19%). Qiagen is headquartered in Venlo, Netherlands.

Ratios

Current vs industry vs history
PE Ratio (TTM) 46.71
Forward PE Ratio 26.60
N/A
PE Ratio without NRI 46.71
Price-to-Owner-Earnings 48.60
PB Ratio 3.29
PS Ratio 5.95
Price-to-Free-Cash-Flow 42.84
Price-to-Operating-Cash-Flow 24.87
EV-to-EBIT 32.14
EV-to-EBITDA 18.86
EV-to-Revenue 6.27
PEG Ratio 4.97
Shiller PE Ratio 69.62
Current Ratio 2.22
Quick Ratio 2.05
Days Inventory 116.19
Days Sales Outstanding 85.45
Days Payable 50.58

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.30

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 168.72
Price-to-Projected-FCF 2.09
Price-to-DCF (Earnings Based) 4.36
Price-to-Median-PS-Value 1.36
Price-to-Peter-Lynch-Fair-Value 7.10
Price-to-Graham-Number 18.68
Earnings Yield (Joel Greenblatt) % 3.11
Forward Rate of Return (Yacktman) % 8.79

More Statistics

Revenue (TTM) (Mil) $ 1,501.85
EPS (TTM) $ 0.82
Beta 0.94
Volatility % 17.41
52-Week Range $ 31.93 - 41.55
Shares Outstanding (Mil) 225.51

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N